Ayurcann Holdings (CSE: AYUR) continues to expand its distribution network. The company this morning reported that it has entered into two separate supply agreements for its medical cannabis products.
The first supply arrangement entered into is with that of Cannmart Inc, effective as of April 15, 2021. The arrangement will see the company provide branded products for resale into the medical cannabis market over a twelve month period.
The company this morning also formally announced that it has previously entered into a supply arrangement with Empress Agri Sales Inc, whom operates as Patient Choice. The arrangement, originally entered into in late December, is valid for a twelve month period wherein Patient Choice facilities direct to patient sales of medical cannabis products, which are completed on a drop shipped basis.
“We are thrilled by this opportunity as we believe these agreements further cement our positioning in the industry as a top quality supplier for leading cannabis brands and direct to medical patients. We have the ability to formulate, manufacture and package quality products at affordable prices and have shown an ability to work with our clients to create products that will resonate in the marketplace.”
Igal Sudman, CEO of Ayurcann
Ayurcann last traded at $0.19 on the CSE.
FULL DISCLOSURE: Ayurcann Holdings is a client of Canacom Group, the parent company of The Deep Dive. The company has been compensated to cover Ayurcann Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
